TrialFrontiers in immunology2022

Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.

Isabel Leroux-Roels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.